Can longer pyrotinib use keep breast cancer at bay?
NCT ID NCT05910398
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial is testing whether extending treatment with the drug pyrotinib (either continuously or in cycles) can help prevent HER2-positive breast cancer from returning. About 488 adults who have already completed initial therapy will be randomly assigned to one of two extended dosing schedules. The main goal is to see which approach improves invasive disease-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pyrotinib
What this could lead to
If successful, this could show that extending pyrotinib treatment (continuously or intermittently) helps keep HER2-positive breast cancer from coming back after initial therapy.
What could go wrong
This is a Phase 3 trial, but it's still recruiting and results aren't yet known. The benefit over standard care may be small, and pyrotinib can cause side effects like diarrhea or liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER INVASIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITINGShanghai, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••